BRIEF-Momenta Pharmaceuticals says positive top-line phase 3 results for M923, a proposed Humira biosimilar
November 29, 2016 at 08:26 AM EST
* Momenta Pharmaceuticals announces positive top-line phase 3 results for M923, a proposed Humira (adalimumab) biosimilar
